logo-loader
viewDynavax Technologies

Dynavax shares set to rise on "encouraging' results of cancer drug

Biopharmaceutical company's treatment is aimed at head and neck cancers

Lab worker with microscope
The shares advanced in pre-market trading

Shares of Dynavax Technologies Corp. (NASDAQ:DVAX) are set to climb after the company reported its immune-oncology drug showed “promising” response rate in treating head and neck cancers.

The stock rose 14% to US$22.44 in pre-market trading.

Dynavax released data in an abstract at the American Association for Cancer research meeting.

The SD-101 drug “showed a promising 40%” overall response rate “indicative of potential activity in the difficult-to-treat setting of head and neck cancers,” MarketWatch reported, citing RBC Capital Markets analyst Brian Abrahams.

 

 

 

Quick facts: Dynavax Technologies

Price: 4.08 USD

NASDAQ:DVAX
Market: NASDAQ
Market Cap: $341.41 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Perseus Mining reports 'another excellent quarter' with production up and...

Perseus Mining Ltd's (ASX:PRU) (TSE:PRU) (FRA:P4Q) (OTCMKTS:PMNXF) Jeff Quartermaine tells Proactive it's been 'another excellent quarter' for the group. "Production's up about 3% and costs down about 7% quarter on quarter. "This is the 11th consecutive quarter that we've produced very...

7 hours, 38 minutes ago

2 min read